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Abstract
Background: P-cadherin (P-cad) is a transmembrane molecule involved in the cell-cell adhesion
and similar to E-cadherin (E-cad), but less investigated in oncology, especially in in vivo studies. Aims
of the present study were to assess the prevalence of P-cad expression in oral squamous cell
carcinoma (OSCC) and to verify whether P-cad can be considered a marker of prognosis in patients
with OSCC.
Methods: In a retrospective study, a cohort of 67 OSCC patients was investigated for P-cad
expression and its cellular localization by immunohistochemistry; some respective healthy margins
of resection were similarly investigated as standard controls. After grouping for P-cad expression,
OSCCs were statistically analyzed for the variables age, gender, histological grading (G), TNM,
Staging, and overall survival rate. Univariate and multivariate analyses were performed.
Results:  37 cases (55.2%) of OSCC showed membranous/cytoplasmic positivity for P-cad,
whereas 30 (44.8 %) were negative. Although with some differences in membranous vs cytoplasmic
localization of P-cad in OSCC with different G, no statistical association was found between P-cad
expression and any variables considered at baseline. In terms of prognostic significance, P-cad non
expression was found to have an independent association with poorer overall survival rate than P-
cad expressing group (P = 0.056); moreover, among P-cad +ve patients the best prognosis was for
those OSCC with membranous (P < 0.0001) than those with cytoplasmic P-cad expression.
Conclusion: On the basis of these results, it is possible to suggest P-cad as an early marker of
poor prognosis. The abnormal or lack of P-cad expression could constitute an hallmark of
aggressive biological behavior in OSCC
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Background
Invasive OSCC, in spite of improved therapeutic proce-
dures, actually show a generally poor prognosis since its
local aggressiveness and metastases. In particular, the inci-
dence of lymph node metastases has been found to be sig-
nificantly associated with several factors; among these,
not only macroscopic parameters, such as clinical stage,
localization and thickness of primary tumours [1-10], but
also microscopic-molecular parameters from differentia-
tion of tumoral cells up to their skill for adherence [11-
14]. Recently, many investigations have been performed
in this latter direction, until to know that intercellular
adhesiveness is mediated by a family of glycoproteins
named cadherins [15]. This family is composed of an
extra-cellular domain, involved in Ca++-dependent
homophilic binding to adjacent cells, a trans-membrane
domain, and an intra-cellular domain which binds to pro-
teins called catenins [16]. In epithelial cells, this adhesive-
ness is mediated by epithelial-cadherin (E-cad), a 120-kd
transmenbrane glycoprotein, localized mainly in the
zonula adherens junctions. The cadherin family includes
also other members: neural-cadherin (N-cadherin) [17],
placental cadherin (P-cad) [18] and liver cell adhesion
molecule (L-CAM), and more than 20 cadherins have
been described in the central nervous system, liver and
vascular endothelial cells and in other tissues and organs
[19,20]. In particular, P-cad is a protein homologous to E-
cad. E-cadherin is involved in the adherens type of inter-
cellular junctions of keratinocytes, while P-cad is detected
on the cell-cell contact surface of basal keratinocytes in
normal mouse and human epidermis and cells migrating
into the suprabasal compartiment down-regulate P-cad
expression. Both these molecules interact with cytoskele-
ton by alpha-catenin.
P-cad is expressed in mouse placenta [18], epithelia [21],
the basal cell of the skin [22,23], playing an important
role in the morphogenesis of epidermis and skin append-
age [22,24,25]. The expression of P-cad in epithelial tis-
sues appears to identify cell populations with proliferative
activity, and its expression decreases as cells differentiate
[23,26].
The possible role exerted by cadherins in human carcino-
genesis has been suggested by a number of studies
[27,28]. Down-regulation of E-cad was reported to be
directly related to invasiveness and progression of many
human epithelial tumours [28], including oral squamous
cell carcinomas (OSCC) [29].
While E-cad expression has been extensively studied in
many forms of human cancers, including OSCC [27,30-
40], less is known about the expression levels of P-cad in
human cancers [23,41-51] and, particularly, in OSCCs in
vivo [35,39,40,52].
Aims of the present study were to assess the prevalence of
P-cad expression in oral squamous cell carcinoma
(OSCC) and to verify whether P-cad can be considered a
marker of prognosis in patients with OSCC.
Methods
Sixty-seven patients affected by histologically proven
OSCC were consecutively recruited among those surgi-
cally treated in a multicentric study between January 1992
and December 1997. The patients, never treated before for
OSCC, included 45 males (67.2%) and 22 females
(32.8%). They ranged in age from 18 to 87 years (median
age 65 years) at the time of admission; 20 (29.8%) had
neck nodes, and none had evidence of distant metastases.
Tumours were classified according to U.I.C.C. 2000 classi-
fication  (UICC 2000), reaching to the following Stage
Grouping: Stage I for 30 OSCC, II for 15, III for 11 and IV
for 11.
Although recruited in different centres, all of OSCCs were
treated according to the common and current Guidelines
dedicated[53]. In particular, sAlthough treated in deiffer-
ent centers, all odf OSCCs were Alkjkkhhhpurgery on T
was the treatment of choice and always performed at the
initial course of the protocol with curative intent (i.e. only
tumour resections in safe margins were done). When radi-
otherapy was considered useful, it was usually done 3
weeks after surgery, with external beam and the dose was
equivalent to 60 or 65 Gy in 6 or 7 weeks. Chemotherapy,
when prescribed, consisted of cisplatin (100 mg/m2 body-
surface area) given as intravenous infusion followed by
continuous 24-hour intravenous infusion of fluorouracil
(1,000 mg/m2 per day) for five days. globally up to 3
cycles. All patients were followed up and examined on a
monthly basis for the first year after treatment, every 2
months for the second year, and every 3 months thereaf-
ter. At our baseline, an overall disease-specific survival was
calculated at 72 months for all patients plus cases cen-
sored (for death).
Immunohistochemistry
5 µm serial sections from routinely formalin-fixed paraf-
fin-embedded blocks were cut for each case, and one sec-
tion stained with haematoxylin-eosin (H.E.) was used to
confirm the histopathological diagnosis. Only sections
showing sufficient epithelium to assess 1000 cells were
considered for this study. In addition, some microscopi-
cally healthy specimens of oral mucosa from juxtaposed
sites to OSCC went to similar investigation as standard
controls.
Immunocytochemistry was then performed on the
remaining sections mounted on poly-L-lysine-coated
glass slides. Endogenous peroxidase was quenched by
incubating the sections for 20 minutes with 0,3%BMC Cancer 2005, 5:63 http://www.biomedcentral.com/1471-2407/5/63
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hydrogen peroxide in methanol. To improve the staining
pattern, the sections were boiled three times for 3 minutes
in 10 mM citrate buffer as an antigen retrieval method. In
order to prevent non-specific binding of antibodies, sec-
tions were then pre-incubated with non-immune mouse
serum (1:20; Dakopatts, Hamburg, Germany) and diluted
in PBS/BSA (1%) for 25 minutes at room temperature.
After washing twice with Tris-HCl buffer, primary anti-
bodies were applied. As positive controls, the immunore-
activity of 5 normal skin sections from leg was evaluated.
A negative control was also performed in each run by sub-
stituting primary antibodies with non-immune serum
(DAKO Antibody Diluent, Dakopatts, Hamburg, Ger-
many). All the slides were washed twice in Tris-HCl buffer
between each step. Commercially available mouse mono-
clonal IgG antibody against P-cad (Transduction Labora-
tories, Lexington, Kentucky, U.S.A.), packaged at 0.25 mg/
ml, was used at a dilution of 1:300. Then two methods
were applied: Labeled streptavidin-biotin-peroxidase
technique (LSAB-HRP) and Labeled Streptavidin-biotin-
alkaline phosphatase technique (LSAB-AP). In LSAB-HRP
technique sequential 20-minute incubation with bioti-
nylated linking antibody and horseradish peroxidase-
labeled streptavidin (Dako LSAB + kit, HRP) were per-
formed at room temperature. The peroxidase activity was
developed by incubation with 3.3'-diaminobenzidine
(DAB, Vector Laboratories, Burlinghame, USA) as a sub-
strate chromogen solution. The slides were then counter-
stained with hematoxylin. In LSAB-AP technique
sequential 20-minute incubations with biotinylated anti-
mouse immunoglogulins and streptavidin conjugated to
alkaline phosphatase were performed. Finally, a new fast
red substrate system (K0597, Dako, Glostrup, Denmark)
was applied as a chromogen solution. The specificity of
this antibody has been described in the literature [42].
Evaluation of immunostaining
The number of P-cad-expressing tumour cells was esti-
mated as a percentage of the final number of 500 neoplas-
tic cells of each case, and scored in two categories: score 0
(≤ 5% of cells were positive), score 1 (P-cad expression in
> 5 of cells %). The expansion of P-cad-positive cells in the
spinous layer was defined as anomalous P-cad expression
[47].
Statistical analysis
Univariate analysis
Differences between P-cad expression values and the vari-
ables considered were analysed by means of Student-New-
mann-Keuls' test (simple or in multiple comparison) and
by ANOVA. The difference was considered significant
when p-value was ≥ 0.05. Disease-specific survival curves
were calculated according to the product-limit method
(Kaplan-Meier algorithm). Time zero was defined as the
date of the patient's initial diagnosis. Patients who are still
alive were included in the total number at risk of death
only up to the time of their last follow-up. Therefore, the
survival rate only changed when death occurred. Patients
dead during the follow-up period (i.e. 72 months) were
considered as censored. The calculated survival rate was
the maximum estimate of the true survival curve. Log rank
test was used to compare survival curves, generated by
stratifications for a variable of interest.
Cox regression analysis
Afterwards, Cox regression analysis was applied to deter-
mine the single contribution of covariates on survival rate.
Cox regression analysis compares survival data while tak-
ing into account the statistical value of independent vari-
ables, such as age and sex, on whether or not an event (i.e.
death) is likely occur. If the associated probability was less
then 5% (p < .05), the difference was considered statisti-
cally significant. In the process of doing the regression
analysis, odds ratio (OR) and 95% confidence interval
(CIs) were calculated. Stepwise Cox analysis allowed us to
detect the variables most associated to survival.
Results
P-cad expression
First of all, the paradigmatic P-cad expression was
obtained from the standard controls (Fig. 1a): in these, in
fact, only a membranous staining was observed at the
basal layer of histologically normal oral epithelium; pre-
dominantly on the membrane of only a thin line of cells
basally located, with occasionally moderate parabasal
staining. The intensity of staining for P-cadherin progres-
sively reduced from basal to parabasal layers and stopped
in the spinous layer. No staining for P-cadherin was
observed in the upper layer.
37 cases (55.2%) OSCC showed membranous/cytoplas-
mic positivity for P-cad (Group P-cad +ve)(Table 1),
whereas 30 (44.8 %) were found negative (Group P-cad -
ve). When examined the cell staining pattern of positive
cases, 25 cases showed a prevalent membranous pattern
(Fig. 1b-c), while 12 had a prevalent cytoplasmic pattern
(Fig. 1d). Worthy of note, within the Group P-cad +ve,
dedifferentiated areas showed both membranous and
cytoplasmic P-cad up-regulation: well-differentiated (G1)
oral carcinomas showed P-cad up-regulation, while P-cad
expression homogeneously reduced in scarcely differenti-
ated oral squamous cell carcinomas (G3), and it shifted to
membranous/cytoplasmic co-localization, predomi-
nantly cytoplasmic in distribution, or alternatively was
absent in a large numbers of cells. Although with these
differences in membranous vs cytoplasmic localization of
P-cad in OSCC with different G, no statistical association
was found between P-cad expression and any variables
(age, sex, G, T, N and Stage grouping) considered at
baseline.BMC Cancer 2005, 5:63 http://www.biomedcentral.com/1471-2407/5/63
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The second part of the analysis planned the study of sur-
vival rates with respect to P-cad expression. Although the
global disease-specific survival rate at 72 months was 51.0
%, irrespectively of the extent of the tumour or treatment
(Fig. 2), the survival rates in the same cohort distributed
according to P-cad expression (Group P-cad +ve vs. P-cad
-ve) was 79.0% vs 40.0% respectively (p-value = 0.04 Log
Rank Test). Survival curves stratified according to P-cad
expression are illustrated in Fig 3. Still in terms of overall
survival, within P-cad +ve group, OSCCs (n = 12) with a
prevalent citoplasmic pattern of P-cad showed poorer sur-
vival rates than those (n = 25) with a prevalent membra-
nous P-cad expression (P <0.0001). Besides the classic
parameters related to survival rate and predictor of a poor
outcome (e.g. G, T, N, stage and recurrence), a stepwise
model introducing P-cad non-expression, without consid-
ering recurrence (parameter with the highest OR), showed
that also P-cad non expression is significantly associated
to survival, together with grading and stage. (Table 2, 3).
Discussion
Both E- and P-cad play a pivotal role in the maintenance
of the epithelial structure, even if they are expressed in dis-
tinct regions of the epithelium. E-cad is expressed on all
epithelial layers, while P-cad is predominantly expressed
in the basal layer of stratified squamous epithelia, the
proliferative compartment [54-59]. E- and P-cad expres-
sion is altered in premalignant and malignant skin
tumors, as demonstrated by reduced E-cad and aberrant P-
cad expression in human squamous cell carcinomas [59],
indicating the importance of coordinated cadherin
expression for maintaining normal epidermal structure
a) Strong basal-parabasal membranous expression of P-cadherin in oral hyperplastic epithelium (LSAB-AP, nuclear counter- staining with haematoxylin, ×106); b) Membranous P-cadherin expression in oral moderately-differentiated SCC (LASB-AP,  ×400); c) Membranous expression of P-cadherin in an area of stromal infiltration from moderately-differentiated OSCC (LASB- AP, nuclear counterstaining with haematoxylin, ×160); d) Cytoplasmic expression of P-cadherin in a case of lowly differentiated  OSCC infiltrating stroma (LSAB-HRP, ×250) Figure 1
a) Strong basal-parabasal membranous expression of P-cadherin in oral hyperplastic epithelium (LSAB-AP, nuclear counter-
staining with haematoxylin, ×106); b) Membranous P-cadherin expression in oral moderately-differentiated SCC (LASB-AP, 
×400); c) Membranous expression of P-cadherin in an area of stromal infiltration from moderately-differentiated OSCC (LASB-
AP, nuclear counterstaining with haematoxylin, ×160); d) Cytoplasmic expression of P-cadherin in a case of lowly differentiated 
OSCC infiltrating stroma (LSAB-HRP, ×250)BMC Cancer 2005, 5:63 http://www.biomedcentral.com/1471-2407/5/63
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[60]. Malignant keratinocytes probably acquire different
mechanisms for regulating the expression of these two
cadherins [61]. P-cad seems to play a role in the mainte-
nance of the epithelial phenotype and may be involved,
together with E-cad, in the final stage of tumor progres-
sion in epidermal carcinogenesis, being a marker of
hyperproliferative activity [47]. Studies on epidermis [26],
gastric epithelium [49], and mammary epithelium [62]
showed that P-cad controls cell proliferation in these tis-
sues. P-cad expression seems to be related to tumour pro-
gression in gastric [50] and gingival carcinomas [35],
while its expression is higher in poorly differentiated than
in well-differentiated lung carcinomas [23]. In particular,
well-differentiated oral carcinomas showed P-cad expres-
sion similar to normal oral mucosa or up-regulated, while
P-cad expression homogeneously reduced in low-differ-
entiated oral squamous cell carcinomas or its localization
shifted to the cytoplasm, in accordance with other studies
on oral mucosa [39] or gastrointestinal mucosa [48,63].
Williams et al. (1988) reported a loss of membranous
immunostaining at the periphery of the islands of carci-
noma with a cytoplasmic immunostaining or a complete
loss[39]. In contrast, towards the centre of the islands the
more differentiated cells showed mild or moderate mem-
branous staining in well- or moderately-differentiated car-
cinomas, reflecting the pattern seen in dysplasia [39].
Recently, also in oral premalignant lesions induced in rats
it has been found that E-cad and P-cad have similar loca-
tion of expression as in OSCC and that just P-cad aberrant
expression could be a strong marker of carcinogen
progression[64].
On the basis of the current knowledge on P-cad and of a
previous research conducted by one of the center
involved[52], in the present research our main goal was to
conduct an in vivo study on the clinical outcome (e.g over-
all survival rate) of OSCC with respect of quality and
quantity of P-cad expression. Hence, in terms of prognos-
tic significance, the lack of P-cad expression (44.8%) was
found to have an independent association with poorer
overall survival rate than P-cad expressing group; moreo-
ver, the abnormal (cytoplasmic) expression of P-cad is
also associated to a poorer prognosis when compared to
that normally membranous. In these latter cases, expres-
sion of P-cad shifted to membranous/cytoplasmic co-
localisation, predominantly cytoplasmic in distribution,
or alternatively was absent from a large numbers of cells.
These two main results are consistent with a very recent
Italian research [52] in which also other tissues (i.e.
lymph node and bone metastases) were investigated.
As regards the lack of P-cad expression, it can be inter-
preted as a late event prior to invasion, as shown by loss
of its expression in dysplasia adjacent to infiltrating
Table 1: OSCC grouped by P-cad expression and their features.
Variables No. P-cad-ve (%) P-cad+ve n. (%) Mean Standard 
deviation
P < 0.05
Cases 67 30(44.8) 37 (55.2)
Age
</= 65 years 32 16 16 1.40 1.10 P = 0.363°
 65 years
35 14 21 1.65 1.13
Sex
Male 45 20 25 1.55 1.07 P = 0.253°
Female 22 10 12 1.50 1.22
Grading
G1 21 6 15 1.85 1.10 P = 0.143*
G2 30 15 15 1.53 1.07
G3 16 9 7 1.12 1.14
Staging
I 30 10 20 1,667 0,4795 P = 0,993*
II 15 6 9 1,600 0,5071
III 11 7 4 1,364 0,5045
IV 11 4 7 1,636 0,5045
°Student-Newmann-Keuls' test.
*One-way Analysis of Variance (ANOVA) and Student-Newman-Keuls Multiple Comparisons Test
¾BMC Cancer 2005, 5:63 http://www.biomedcentral.com/1471-2407/5/63
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carcinomas [39]. The loss of P-cad expression probably
comes after P-cad cytoplasmic relocalization. Loss of P-
cad expression in OSCC is associated with tumour inva-
sion, while P-cad membranous staining in OSCC is prob-
ably due to the up-regulation seen in tumour cell lines
and dysplasias. Therefore, in the initial phase of tumour
growth the high expression of P-cad may be crucial in the
formation of a tumour mass which is ready to progress
and metastasize [50]. Whereas anomalous P-cad expres-
sion in the spinous layer of epithelium overlying tumour
can be a biological marker for keratinocyte atypia and/or
premalignant changes[65]. In fact, the continued expres-
sion of P-cad in the invasive cells can contribute to the
maintenance of the epithelioid phenotype of the carci-
noma cells [65]. An experimental study on squamous cell
carcinoma cell lines showed aberrant expression in cancer
cells, whereas E-cad expression was reduced [61]. SCC
cells probably acquire the ability to express P-cad and this
molecule plays a role in tumour progression [61]. Ele-
vated [Ca++] determined increased cell-surface P-cad
expression in SCC cell lines by up-regulation of de novo
P-cad synthesis, while in normal keratinocytes calcium-
induced cell-surface P-cad expression is a result of the
translocation of pre-formed P-cad from the cytosol with-
out up-regulation of P-cad synthesis [60]. These results
suggest the existence of a unique mechanism for regulat-
ing the P-cad expression gene in tumour cells.
Bagutti et al. (1998) showed no correlation between P-cad
expression and differentiation of tumour cells[40], while
Sakaki et al. (1994) showed a complete loss of P-cad
expression in poorly-differentiated gingival SCC[35].
Cytoplasmic relocalization or loss of P-cad expression
may be responsible, together with other known/unknown
upregulated oncogenes and downregulated tumour sup-
pressor genes, for the later stages of tumour progression,
such as invasive growth and metastasis [50].
On the basis of our present results, no association was
found between P-cad expression and any of parameters
considered (age, gender, G, T, N, Stage grouping), datum
Overall disease-specific survival rate at 72-months (+ cen- sored cases) Figure 2
Overall disease-specific survival rate at 72-months (+ cen-
sored cases). Disease-specific survival rate calculated according to P-cad  categories Figure 3
Disease-specific survival rate calculated according to P-cad 
categories. Log Rank 3.38, 1 df p-value = 0.0661 (+ censored 
cases)BMC Cancer 2005, 5:63 http://www.biomedcentral.com/1471-2407/5/63
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not consistent with the Italian research cited above [52],
probably due to the different sample size.
A limit of the present study could be the fact that assess-
ment of P-cad expression was done according to two
scores; a larger sample size is warranted in the future in
order to score OSCC in several groups according to P-cad
expression with respect to prognosis.
The main present findings, based on overall survival rate,
emphasise the role of P-cad expression as an early marker
of OSCC prognosis, earlier than recurrence, as being the
best marker, unfortunately, detected only after its onset.
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